Sunesis To Present At Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences.

Daniel Swisher, Chief Executive Officer of Sunesis, will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 2:00 PM Eastern Time at The Sheraton New York Times Square Hotel in New York City.

Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 3:30 PM Eastern Time in New York City.

A live webcast of the presentations will be available on the Sunesis website at http://ir.sunesis.com. A replay of each webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, Qinprezo™ (vosaroxin), in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

For additional information on Sunesis, please visit http://www.sunesis.com.
CONTACT: Investor and Media Inquiries:         David Pitts         Argot Partners         212-600-1902                  Eric Bjerkholt         Sunesis Pharmaceuticals Inc.         650-266-3717                  Eliza Schleifstein         Argot Partners         917-763-8106         eliza@argotpartners.com

Sunesis Pharmaceuticals, Inc. Logo

If you liked this article you might like

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

5 Stocks Under $10 Set to Soar

4 Biotech Stocks Under $10 to Trade for Breakouts

Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More